Technical Analysis for ARDX - Ardelyx, Inc.

Grade Last Price % Change Price Change
C 6.795 0.07% 0.01
ARDX closed up 2.26 percent on Friday, May 14, 2021, on 52 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Up Down Up
Historical ARDX trend table...

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.07%
Wide Bands Range Expansion 0.07%
Oversold Stochastic Weakness 0.07%
New Downtrend Bearish 2.33%
Wide Bands Range Expansion 2.33%
Oversold Stochastic Weakness 2.33%
Shooting Star Candlestick Bearish 1.12%
Doji - Bearish? Reversal 1.12%
Wide Bands Range Expansion 1.12%
Oversold Stochastic Weakness 1.12%
Older End-of-Day Signals for ARDX ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Rose Above Previous Day's High about 2 hours ago
Up 1% about 2 hours ago
Down 1% about 2 hours ago
Up 3% 3 days ago
Possible Inside Day 3 days ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Ardelyx, Inc. Description

Ardelyx, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics to treat cardio-renal, gastrointestinal (GI), and metabolic diseases. Its lead product candidate is Tenapanor, a small molecule, orally administered inhibitor of NHE3, which is in three ongoing Phase II clinical trials for the treatment of patients with ESRD-HD and chronic kidney disease, as well as for constipation-predominant irritable bowel syndrome. The company also evaluates small molecule NaP2b inhibitors for the treatment of hyperphosphatemia in end stage renal disease. In addition, its other discovery and lead development programs consist of RDX009, RDX013, and RDX020 programs that are in research phase focusing on cardio-renal, GI, and metabolic diseases. Ardelyx, Inc. has a collaboration partnership agreement with AstraZeneca AB for the development and commercialization of tenapanor. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was founded in 2007 and is headquartered in Fremont, California.


Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Gastrointestinal Phosphate Kidney Disease Chronic Kidney Disease Metabolic Disease Renal Disease Metabolic Diseases End Stage Renal Disease Stage Renal Disease Molecule Therapeutics Irritable Bowel Syndrome Constipation Rockwell Medical Esrd Hyperphosphatemia

Is ARDX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 9.23
52 Week Low 4.96
Average Volume 2,368,365
200-Day Moving Average 6.43
50-Day Moving Average 7.21
20-Day Moving Average 7.52
10-Day Moving Average 6.70
Average True Range 0.52
ADX 25.73
+DI 16.10
-DI 31.18
Chandelier Exit (Long, 3 ATRs ) 7.69
Chandelier Exit (Short, 3 ATRs ) 7.77
Upper Bollinger Band 9.30
Lower Bollinger Band 5.75
Percent B (%b) 0.29
BandWidth 47.13
MACD Line -0.25
MACD Signal Line -0.12
MACD Histogram -0.1264
Fundamentals Value
Market Cap 612.79 Million
Num Shares 90.2 Million
EPS -1.66
Price-to-Earnings (P/E) Ratio -4.09
Price-to-Sales 66.39
Price-to-Book 4.34
PEG Ratio -0.08
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 7.12
Resistance 3 (R3) 7.10 6.97 7.07
Resistance 2 (R2) 6.97 6.89 6.98 7.05
Resistance 1 (R1) 6.88 6.83 6.93 6.90 7.03
Pivot Point 6.75 6.75 6.77 6.76 6.75
Support 1 (S1) 6.66 6.67 6.71 6.68 6.55
Support 2 (S2) 6.53 6.61 6.54 6.53
Support 3 (S3) 6.44 6.53 6.52
Support 4 (S4) 6.46